Published in J Neural Transm (Vienna) on October 22, 2017
Multiple-system atrophy. N Engl J Med (2015) 3.86
A potent pressor response elicited by drinking water. Lancet (1999) 3.02
Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA (1997) 2.63
Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med (2008) 2.38
Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev (2005) 2.32
Pyridostigmine for treatment of neurogenic orthostatic hypotension [correction of hypertension]--a follow-up survey study. Clin Auton Res (2005) 2.15
Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care (2004) 1.99
Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci (2011) 1.82
Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry (2003) 1.81
Safety and side effect profile of fluoxetine. Expert Opin Drug Saf (2004) 1.75
Prevalence of orthostatic hypotension. Clin Auton Res (2008) 1.75
Acarbose, an alpha-glucosidase inhibitor, attenuates postprandial hypotension in autonomic failure. Hypertension (2007) 1.70
Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension (2010) 1.69
A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology (1998) 1.67
Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology (1988) 1.61
Droxidopa in neurogenic orthostatic hypotension. Expert Rev Cardiovasc Ther (2015) 1.61
Water drinking as a treatment for orthostatic syndromes. Am J Med (2002) 1.60
The prevalence and association of neck (coat-hanger) pain and orthostatic (postural) hypotension in human spinal cord injury. Spinal Cord (2002) 1.55
Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet (2005) 1.55
Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med (1993) 1.54
The effect of intranasal desmopressin on nocturnal waking in urination in multiple system atrophy patients with nocturnal polyuria. Clin Auton Res (2003) 1.53
The pressor response to water drinking in humans : a sympathetic reflex? Circulation (2000) 1.52
Sodium paradoxically reduces the gastropressor response in patients with orthostatic hypotension. Hypertension (2006) 1.51
Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation (2009) 1.50
Supine hypertension in Parkinson's disease and multiple system atrophy. Clin Auton Res (2016) 1.40
Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol (2006) 1.38
EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol (2006) 1.37
Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord (2010) 1.34
Water drinking and the heart. Lancet (1999) 1.34
Oral yohimbine in human autonomic failure. Neurology (1987) 1.31
Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation (2003) 1.30
Endogenous restoration of noradrenaline by precursor therapy in dopamine-beta-hydroxylase deficiency. Lancet (1987) 1.20
Contrasting actions of pressor agents in severe autonomic failure. Am J Med (1998) 1.20
The prevalence of orthostatic hypotension during physiotherapy treatment in patients with an acute spinal cord injury. Spinal Cord (2000) 1.18
Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord (2011) 1.16
Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology (2014) 1.15
Treatment of orthostatic hypotension with erythropoietin. N Engl J Med (1993) 1.13
Orthostatic Hypotension: Epidemiology, Prognosis, and Treatment. J Am Coll Cardiol (2015) 1.13
The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Br Med J (Clin Res Ed) (1986) 1.11
Ergot and its alkaloids. Am J Pharm Educ (2006) 1.11
The influence of food on postural hypotension in three groups with chronic autonomic failure--clinical and therapeutic implications. J Neurol Neurosurg Psychiatry (1991) 1.10
Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure. Clin Auton Res (1995) 1.10
Comparative effects of clonidine and dihydroergotamine on venomotor tone and orthostatic tolerance in patients with severe hypoadrenergic orthostatic hypotension. Am J Med (2002) 1.09
Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension (2014) 1.09
Synergistic effect of norepinephrine transporter blockade and α-2 antagonism on blood pressure in autonomic failure. Hypertension (2012) 1.09
Hemodynamic and humoral effects of caffeine in autonomic failure. Therapeutic implications for postprandial hypotension. N Engl J Med (1985) 1.09
The anemia of primary autonomic failure and its reversal with recombinant erythropoietin. Ann Intern Med (1994) 1.09
Physical manoeuvres for combating orthostatic dizziness in autonomic failure. Lancet (1992) 1.08
Use of lower abdominal compression to combat orthostatic hypotension in patients with autonomic dysfunction. Clin Auton Res (2004) 1.06
The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. Parkinsonism Relat Disord (2011) 1.06
Efficacy of compression of different capacitance beds in the amelioration of orthostatic hypotension. Clin Auton Res (1997) 1.05
Developmental abnormalities, blood pressure variability and renal disease in Riley Day syndrome. J Hum Hypertens (2011) 1.05
The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology (1999) 1.03
Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). Mov Disord (2014) 1.02
Effect of L-threo-3,4-dihydroxyphenylserine on muscle sympathetic nerve activities in Shy-Drager syndrome. Neurology (1988) 1.02
Survival in synucleinopathies: A prospective cohort study. Neurology (2015) 1.02
Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. Am J Med (1995) 1.01
Midodrine. A review of its therapeutic use in the management of orthostatic hypotension. Drugs Aging (1998) 0.99
Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension (2007) 0.99
Ambulatory blood pressure in patients with Parkinson's disease without and with orthostatic hypotension. Clin Auton Res (1992) 0.99
Osmosensitive mechanisms contribute to the water drinking-induced pressor response in humans. Neurology (2005) 0.98
Fludrocortisone and sleeping in the head-up position limit the postural decrease in cardiac output in autonomic failure. Clin Auton Res (2000) 0.97
Treatment of orthostatic hypotension with sleeping in the head-up tilt position, alone and in combination with fludrocortisone. J Intern Med (1992) 0.97
Treatment of autonomic neuropathy with a somatostatin analogue SMS-201-995. Lancet (1986) 0.96
Postural hypotension and dizziness in a general aged population: a four-year follow-up of the Helsinki Aging Study. J Am Geriatr Soc (1996) 0.96
Cardiovascular, biochemical and hormonal changes during food-induced hypotension in chronic autonomic failure. J Neurol Sci (1989) 0.96
Preliminary observations on the use of midodrine in treating orthostatic hypotension in familial dysautonomia. J Auton Nerv Syst (1995) 0.96
Effects of leg muscle pumping and tensing on orthostatic arterial pressure: a study in normal subjects and patients with autonomic failure. Clin Sci (Lond) (1994) 0.96
Fluoxetine hydrochloride for the treatment of severe refractory orthostatic hypotension. Am J Med (1994) 0.95
The potential prognostic role of cardiovascular autonomic failure in α-synucleinopathies. Eur J Neurol (2012) 0.95
L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res (2001) 0.95
Pressor effect of inhaled ergotamine in orthostatic hypotension. Am J Cardiol (1990) 0.94
Role of physical countermaneuvers in the management of orthostatic hypotension: efficacy and biofeedback augmentation. Mayo Clin Proc (1996) 0.93
Physical manoeuvres that reduce postural hypotension in autonomic failure. Clin Auton Res (1993) 0.92
Patterns of neuropathy and autonomic failure in patients with amyloidosis. Mayo Clin Proc (2008) 0.91
Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in dopamine-beta-hydroxylase deficiency. Lancet (1987) 0.91
Manipulation of norepinephrine metabolism with yohimbine in the treatment of autonomic failure. J Clin Pharmacol (1994) 0.90
Effect of meal size on post-prandial blood pressure and on postural hypotension in primary autonomic failure. Clin Auton Res (1996) 0.90
Haemodynamics of the pressor effect of oral water in human sympathetic denervation due to autonomic failure. Clin Sci (Lond) (2001) 0.90
Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A). J Parkinsons Dis (2014) 0.89
Effects of midodrine on exercise-induced hypotension and blood pressure recovery in autonomic failure. J Appl Physiol (1985) (2004) 0.89
Effects of the peptide release inhibitor, octreotide, on daytime hypotension and on nocturnal hypertension in primary autonomic failure. J Hypertens (1995) 0.88
Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2012. Eur J Neurol (2013) 0.87
Shy-Drager syndrome. Effect of fludrocortisone and L-threo-3,4-dihydroxyphenylserine on the blood pressure and regional cerebral blood flow. J Neurol Neurosurg Psychiatry (1990) 0.87
Clinical pharmacokinetics of ergotamine in migraine and cluster headache. Clin Pharmacokinet (1985) 0.87
Treatment of orthostatic hypotension with octreotide. J Clin Endocrinol Metab (1989) 0.87
Water potentiates the pressor effect of ephedra alkaloids. Circulation (2004) 0.86
Treatment of orthostatic hypotension with dihydroergotamine and caffeine. Ann Intern Med (1986) 0.86
The potent pressor effect of phenylpropanolamine in patients with autonomic impairment. JAMA (1987) 0.86
Contrasting effects of acute and chronic volume expansion on orthostatic blood pressure control in a patient with autonomic circulatory failure. Neth J Med (1991) 0.85
The effects of water ingestion on orthostatic hypotension in two groups of chronic autonomic failure: multiple system atrophy and pure autonomic failure. J Neurol Neurosurg Psychiatry (2004) 0.84
Acetylcholinesterase inhibition in patients with orthostatic intolerance. J Clin Neurophysiol (2006) 0.84
Falls in ambulatory non-demented patients with Parkinson's disease. J Neural Transm (Vienna) (2015) 0.83
Treatment of orthostatic hypotension in Shy-Drager syndrome with DL-threo-3,4-dihydroxyphenylserine: a case report. Eur Neurol (1985) 0.82
Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension (2014) 0.82
Prevention of glucose-induced hypotension by the somatostatin analogue octreotide (SMS 201-995) in chronic autonomic failure: haemodynamic and hormonal changes. Clin Sci (Lond) (1989) 0.82
Treatment of orthostatic hypotension with midodrine and octreotide. J Clin Endocrinol Metab (1998) 0.82
New developments in the management of neurogenic orthostatic hypotension. Curr Cardiol Rep (2014) 0.82
Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord (2007) 0.82
Pharmacodynamic actions of midodrine, a new alpha-adrenergic stimulating agent, and its main metabolite, ST 1059. Arzneimittelforschung (1976) 0.80
Correction to: Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. J Neural Transm (Vienna) (2017) 0.75